Kym N. Lowes

Kym N. Lowes

Auto-generated profile, based on publicly available information

Kym N. Lowes

Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2015 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JLJoel D. Leverson
Joel D. Leverson
DPDarren C. Phillips
Darren C. Phillips
MMMichael J. Mitten
Michael J. Mitten
EBErwin R. Boghaert
Erwin R. Boghaert
DDDolores Diaz
Dolores Diaz
ASAndrew J. Souers
Andrew J. Souers
Selective inhibition of BCL-X L synergizes with docetaxel to inhibit the growth of solid tumors but does not inhibit granulopoiesis.

1 February 1999 in The American Journal of Pathology
Verified
Journal Article
Closed access
KLKym N. Lowes
Kym N. Lowes
BBBarbara A. Brennan
Barbara A. Brennan
GYGeorge Cheng Yeoh
George Cheng Yeoh
JOJohn Olynyk
John Olynyk

21 April 2013 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
GLGuillaume Lessene
Guillaume Lessene
PCPeter E Czabotar
Peter E Czabotar
Brad E. SleebsBrad E. Sleebs
Brad E. Sleebs
KZKerry Zobel
Kerry Zobel
KLKym N Lowes
Kym N Lowes
KWKeith G Watson
Keith G Watson

1 July 2014 in PLOS Biology
Verified
Journal Article
Open access
PDF file
Brad E. SleebsBrad E. Sleebs
Brad E. Sleebs
SLSash Lopaticki
Sash Lopaticki
DMDanushka S. Marapana
Danushka S. Marapana
MOMatthew T. O'Neill
Matthew T. O'Neill
PRPravin Rajasekaran
Pravin Rajasekaran
JBJustin A. Boddey
Justin A. Boddey
The malaria parasite Plasmodium falciparum exports several hundred proteins into the infected erythrocyte that are involved in cellular remodeling and severe virulence. The export mechanism involves the Plasmodium export element (PEXEL), which is a cleavage site for the parasite protease, Plasmepsin V (PMV). The PMV gene is refractory to deletion, suggesting it is essential, but definitive proof is lacking. Here, we generated a PEXEL-mimetic inhibitor that potently blocks the activity of PMV isolated from P. falciparum and Plasmodium vivax. Assessment of PMV activity in P. falciparum revealed PEXEL cleavage occurs cotranslationaly, similar to signal peptidase. Treatment of P. falciparum–infected erythrocytes with the inhibitor caused dose-dependent inhibition of PEXEL processing as well as protein export, including impaired display of the major virulence adhesin, PfEMP1, on the erythrocyte surface, and cytoadherence. The inhibitor killed parasites at the trophozoite stage and knockdown of PMV enhanced sensitivity to the inhibitor, while overexpression of PMV increased resistance. This provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival in human erythrocytes and validates PMV as an antimalarial drug target. To survive within human red blood cells, malaria parasites must export a catalog of proteins that remodel the host cell and its surface. This enables parasites to acquire nutrients from outside the cell and to modify the cell surface in order to evade host defenses. Protein export involves proteolytic cleavage of the Plasmodium Export Element (PEXEL) by the aspartyl protease Plasmepsin V. We report here the development of a small molecule inhibitor that closely mimics the natural PEXEL substrate and blocks the activity of Plasmepsin V from the malarial parasites Plasmodium falciparum and Plasmodium vivax. The inhibitor impairs export and cellular remodeling and kills P. falciparum at the ring-trophozoite transition, providing direct evidence that Plasmepsin V activity is essential for export of PEXEL proteins and parasite survival within the host. These findings validate Plasmepsin V as a highly conserved antimalarial drug target.

1 January 2009 in Molecular Cell
Verified
Journal Article
Closed access
EDElinor Dehan
Elinor Dehan
FBFlorian Bassermann
Florian Bassermann
DGDaniele Guardavaccaro
Daniele Guardavaccaro
GVGaia Vasiliver-Shamis
Gaia Vasiliver-Shamis
MCMichael Cohen
Michael Cohen
MPMichele Pagano
Michele Pagano

14 January 2016 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
AJA V Jacobsen
A V Jacobsen
KLK N Lowes
K N Lowes
MTM C Tanzer
M C Tanzer
ILI S Lucet
I S Lucet
JHJ M Hildebrand
J M Hildebrand
JMJ M Murphy
J M Murphy
Necroptosis is a caspase-independent form of regulated cell death that has been implicated in the development of a range of inflammatory, autoimmune and neurodegenerative diseases. The pseudokinase, Mixed Lineage Kinase Domain-Like (MLKL), is the most terminal known obligatory effector in the necroptosis pathway, and is activated following phosphorylation by Receptor Interacting Protein Kinase-3 (RIPK3). Activated MLKL translocates to membranes, leading to membrane destabilisation and subsequent cell death. However, the molecular interactions governing the processes downstream of RIPK3 activation remain poorly defined. Using a phenotypic screen, we identified seven heat-shock protein 90 (HSP90) inhibitors that inhibited necroptosis in both wild-type fibroblasts and fibroblasts expressing an activated mutant of MLKL. We observed a modest reduction in MLKL protein levels in human and murine cells following HSP90 inhibition, which was only apparent after 15 h of treatment. The delayed reduction in MLKL protein abundance was unlikely to completely account for defective necroptosis, and, consistent with this, we also found inhibition of HSP90 blocked membrane translocation of activated MLKL. Together, these findings implicate HSP90 as a modulator of necroptosis at the level of MLKL, a function that complements HSP90’s previously demonstrated modulation of the upstream necroptosis effector kinases, RIPK1 and RIPK3.